Pharmaceutical

GSK concludes Aiolos Bio acquisition for $1.4bn

GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.

Feb 16, 2024 - 18:00
GSK concludes Aiolos Bio acquisition for $1.4bn
GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.
Read the original article

Tags:

Previous Article

Xyphos and Kelonia link for immuno-oncology drug development

Next Article

Psychedelic treatments for mental health: Is there substance behind the hype?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BARDA and Tiba Biotech link to develop ‘flu therapeutics

BARDA and Tiba Biotech link to develop ‘flu therapeutics

Jul 12, 2024

Rats have an imagination, too, researchers show with brain implants

Rats have an imagination, too, researchers show with br...

Nov 3, 2023

Johnson & Johnson gets grant for heart ultrasound image...

Apr 25, 2024